On 8/15/24, Atara Biotherapeutics Inc (NASDAQ: ATRA) stock suffered a major decline of -11.5%, closing at $6.83. Moreover, this decline was accompanied by unusually high trading volume at 170% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -8.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ATRA is expected to continue to be Value Creation neutral.
Atara Biotherapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment